Who Is Most Likely to Get Lupus Nephritis? Symptoms
Title: Who Is Most Likely to Get Lupus Nephritis? SymptomsCategory: Diseases and ConditionsCreated: 3/16/2022 12:00:00 AMLast Editorial Review: 3/16/2022 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 16, 2022 Category: Rheumatology Source Type: news
Biocon Biologics says clinical study for drug Itolizumab initiated in India after approval from DCGI
Biocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 23, 2021 Category: Pharmaceuticals Source Type: news
How Long Can You Live With Lupus Nephritis?
Title: How Long Can You Live With Lupus Nephritis?Category: Diseases and ConditionsCreated: 12/9/2021 12:00:00 AMLast Editorial Review: 12/9/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - December 9, 2021 Category: Nutrition Source Type: news
What Are the Advantages and Disadvantages of Different Renal Replacement Therapies?
Discussion
Kidneys are amazing in that they filter the blood, eliminate toxins, balance fluids and electrolytes plus have a lot of reserve to do the job they need to do even when injured. Therefore, depending on the problem, chronic renal disease (CRD) often allows time before renal replacement therapy (RRT) is needed. RRT currently is dialysis (peritoneal or hemodialysis) or renal transplant. In general, the patient’s own kidneys do the best job for them but there is always a balance between the problems of CRD and its management, versus the potentially improved renal function with RRT. RRT itself though has a diffe...
Source: PediatricEducation.org - September 13, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Experts Debate Merits of Dual Therapy for Lupus Nephritis Experts Debate Merits of Dual Therapy for Lupus Nephritis
Brad Rovin, MD, and Richard Furie, MD, discussed the merits of dual therapy with voclosporin or belimumab in lupus nephritis but said response rates leave a lot of room for improvement.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 19, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Add-On Voclosporin Improves Outcome in Lupus Nephritis Add-On Voclosporin Improves Outcome in Lupus Nephritis
Voclosporin plus MMF and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news
How Is Lupus Nephritis Treated
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 12, 2021 Category: General Medicine Source Type: news
What Are The Six Classes of Lupus Nephritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 7, 2021 Category: General Medicine Source Type: news
B Cells in Relapsing Lupus Nephritis and Cutaneous Vasculitis B Cells in Relapsing Lupus Nephritis and Cutaneous Vasculitis
A case of a woman with systemic lupus erythematosus whose nephritis and cutaneous vasculitis were refractory to treatment.HSS Grand Rounds Complex Cases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 28, 2021 Category: Consumer Health News Tags: Rheumatology Clinical Case Source Type: news
Patient Benefits Justify Price of New Lupus Nephritis Drugs Patient Benefits Justify Price of New Lupus Nephritis Drugs
Prices of two new drugs approved by the FDA for lupus nephritis are in reasonable alignment with their estimated benefits for patients with the disease, a report indicates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 26, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news
Study examines role of biomarkers to evaluate kidney injury in cancer patients
(Mayo Clinic) A study by Mayo Clinic researchers published in Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 3, 2021 Category: Cancer & Oncology Source Type: news
Study examines role of biomarkers to evaluate kidney injury in cancer patients undergoing immunotherapy
ROCHESTER, Minn. -- A study by Mayo Clinic researchers published in Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells. "Immune checkpoint inhibitors have [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 3, 2021 Category: Databases & Libraries Source Type: news
FDA Approves Voclosporin for Lupus Nephritis FDA Approves Voclosporin for Lupus Nephritis
Lupkynis is a calcineurin-inhibitor immunosuppressant, and is the first oral medication to show effectiveness in lupus nephritis, according to the company.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 27, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
FDA Approves Lupkynis (voclosporin) for Adult Patients with Active Lupus Nephritis
VICTORIA, British Columbia& ROCKVILLE, Md.-- January 22, 2021 -- Aurinia Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lupkynis (voclosporin) in combination with a background... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 22, 2021 Category: Drugs & Pharmacology Source Type: news
The 2018 and 2003 ISN/RPS Classification for Lupus Nephritis The 2018 and 2003 ISN/RPS Classification for Lupus Nephritis
How does the 2018 revised ISN/RPS classification for lupus nephritis differ from that of the 2003 classification?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
